Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05768711 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR)

Study acronym: AVENHIR
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date changed from estimate of May 2026 to Jun 16, 2026
    • Eligibility criteria expanded, about 22 words
    • Secondary endpoints: details revised at 5 of 15 entries
    • Site details revised at 3 of 24 sites
  2. Primary completion date: Feb 2026 to May 2026v9
  3. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 24 of 24 sites
    v8
  4. Study sites: 23 to 24
    • Eligibility criteria expanded, about 1 word
    • Study description shortened, about 2 words
    v7
  5. Study sites: 19 to 23v6
Show 4 earlier versionsHide 4 earlier versions
  1. Site details revised at 1 of 19 sitesv5
  2. Trial status: Not Yet Recruiting to Recruitingv4 Show 4 more changesShow less
    • Study sites: 15 to 19
    • Primary completion date: Jan 2026 to Feb 2026
    • Study completion date: Sep 2028 to Oct 2028
    • Start date changed from estimate of Sep 2023 to Oct 4, 2023
  3. Start date: May 2023 to Sep 2023
    • Primary completion date: Sep 2025 to Jan 2026
    • Study completion date: Mar 2028 to Sep 2028
    v3
  4. Start date: Mar 2023 to May 2023v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Open-label phase II, single arm, multicenter study with safety run-in to evaluate the efficacy and safety of Azacitidine combined with Venetoclax in patients with higher-risk chronic myelomonocytic leukemia
Trial Details
NCT Number NCT05768711
Lead Sponsor Groupe Francophone des Myelodysplasies
Collaborators: AbbVie
Conditions
(from sponsor)		 Chronic Myeloid Leukemia
Related terms Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Enrollment 44 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov